# enGene Therapeutics Inc.: Form 8-K, filed Dec 19, 2024

- Company: [enGene Therapeutics Inc.](/companies/engn.md) (CIK 1980845)
- Form: 8-K
- Filed: 2024-12-19
- Accepted by EDGAR: Dec 19, 2024, 16:09 ET
- Period: 2024-12-19
- Accession: 0000950170-24-138446
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1980845/000095017024138446/engn-20241219.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1980845/000095017024138446/

## Items reported

- Item 1.01: Entry into a material agreement
- Item 2.02: Results of operations
- Item 2.03: New direct financial obligation
- Item 9.01: Financial statements and exhibits

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1980845/000095017024138446/engn-20241219.htm

Filed Dec 19, 2024.
Source: SEC EDGAR, the filing index for accession 0000950170-24-138446. Last ingested by Listed: Oct 24, 2026, 15:16 ET. No prices; not investment advice.